Sailybio
Shanghai, China | +86 21 5808 0192
Menu
Shanghai, China
+86 21 5808 0192

Loading product

Please wait while the product information is retrieved.

Product unavailable

We could not load this product.

Product

Category: Product
Antibody-Dependent Cellular Phagocytosis Assay (ADCP)
面议
ADCP assay, a mature system for evaluating antibody-dependent macrophage phagocytosis, supports efficacy assessment of CD47/CD20-targeting antibodies, with dose-dependent phagocytosis confirmed in case studies.
Service Advantages:

Industrialized cell isolation and preparation workflows with full-process quality control management.

Stable and compliant immune cell sourcing shortens experimental cycles and ensures consistency of conclusions.

Based on a donor pool of more than 2,000 donors, donors with stronger immune responses can be pre-screened, accelerating development and reducing R&D costs.

Safe and compliant project services that satisfy the compliance documentation requirements for new drug application regulatory submissions.

Data Presentation:

Macrophages (M2) are used as effector cells and Raji cells as target cells.

CD47 and CD20 antibodies induce macrophages to exert ADCP in a dose-dependent manner.


Figure: CD47/CD20 antibody-

The ADCP assay is a very important component of antibody pharmacodynamic evaluation and represents a mature and robust assay system for macrophage induction and phagocytosis experiments.


SailyBio's ADCP assay service centers on macrophage phagocytosis to systematically evaluate the antibody-dependent cellular phagocytosis function of antibodies, supporting the efficacy evaluation of antibody drugs targeting CD47, CD20, and other targets. Case data demonstrate that CD47/CD20 antibodies mediate macrophage phagocytosis in a dose-dependent manner.

Copyright @ 2026 SAILYBIO. All rights reserved
Powerby Feedback Follow Data